Related Experiment Video

Updated: May 12, 2026

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Matrix metalloproteinase-9 -1562C/T promoter polymorphism confers risk for COPD: a meta-analysis

Lei Chen1, Tao Wang, Lian Liu

  • 1Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.

Plos One
|April 5, 2013
PubMed
Abstract

Insights

This meta-analysis found that the MMP-9 -1562 C/T gene polymorphism is associated with chronic obstructive pulmonary disease (COPD) risk, particularly when using healthy smokers as controls. The MMP-1 -1607 G/GG polymorphism showed no significant association with COPD susceptibility.

Area of Science:

  • Genetics and Molecular Biology
  • Respiratory Medicine
  • Epidemiology

Background:

  • Inconsistent findings exist regarding the role of matrix metalloproteinase (MMP) gene polymorphisms in chronic obstructive pulmonary disease (COPD) development.
  • This study focuses on MMP-1 -1607G/GG and MMP-9 -1562C/T promoter polymorphisms.

Purpose of the Study:

  • To assess the association between MMP-1 -1607G/GG and MMP-9 -1562C/T promoter polymorphisms and COPD susceptibility.
  • To clarify the inconsistent results reported in previous studies.

Main Methods:

  • A meta-analysis of published case-control studies from Pubmed and CNKI databases.
  • Data extraction and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated.
  • Stratification by ethnicity and source of controls was performed, including Bonferroni correction.

Main Results:

  • A total of fourteen case-control studies were included.
  • MMP-9 -1562 C/T polymorphism was associated with COPD risk (dominant model: OR=1.46, p=0.04).
  • MMP-1 -1607G/GG showed no overall correlation, but associations were found in specific ethnic groups and with smoker-based controls for MMP-9.

Conclusions:

  • MMP-9 -1562 C/T polymorphism is associated with COPD risk, especially when healthy smokers are used as controls.
  • MMP-1 -1607 G/GG polymorphism was not found to be associated with COPD risk in this meta-analysis.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...